The third quarter was a breakthrough quarter for ODI Pharma AB (”ODI Pharma” or the ”Company”), with...
Windon Energy Group AB (”Windon” eller ”Bolaget”) första kvartal var tuffare avseende de rapporterad...
Edyoutec AB (”edyoutec” eller ”Bolaget”), redovisade under kv1 2024 signifikant lägre omsättning än ...
Redeye updates its estimates on Artificial Solutions, which continues to grow strongly, underpinned ...
NOSIUM har levererat en solid inledning av år 2024, där Q1-rapporten visade på en minskad nettoomsät...
Konsumentmarknaden är fortsatt svag men sjunkande räntor och ökat intresse för batterilagring ger ho...
With two noteworthy deals in Q2, a comprehensive agreement for digital management with Pareto Busine...
Q-linea and its distribution partners continue to advance pilot and tender process activities, leadi...
Zoomability Int AB (”Zoomability” eller ”bolaget”) meddelade den 2 juni att bolagets konvertibla lån...
Windon Energy Group meddelade den 3 juni år 2024 att bolaget har erhållit de första ordrarna på den ...
Redeye endorses today’s news that Egetis has received a “Promising Innovative Medicine (PIM) designa...
Despite lowering our short-term forecasts, Redeye retains its positive stance on Speqta following th...
IRLAB Therapeutics is swiftly progressing with the Phase I trial for IRL757, with the first particip...
Redeye reviews the Integrum case and provides a more clear-cut take on its longer-term outlooks.
Redeye saw a mixed Q1 report, as sales and gross margins did not deviate much from our expectations,...
Redeye comments on the subscription price and the strong start of the Terclara launch.
Q1: sales SEK 0.82m, adj. EBIT -12m, no deliveries Q2 to be more eventful, SEK 12m of orders announc...
Redeye comments on the Q1 report 2024. The rest of 2024 is funded through the recent rights issue, i...
The Committee for Medicinal Products for Human Use (CHMP) of EMA recommends a full marketing author...
Redeye comments on the positive outcome of Annexin’s rights issue.
